Given the substantial unmet need for mechanistically novel treatments for PTSD, the emerging pharmacological and behavioral profile of TAAR1 agonists warrants dedicated investigation, particularly in light of their capacity to modulate neural circuits central to stress responsivity, emotional regulation, and monoaminergic homeostasis. The gene discussed is TAAR1; the disease is post-traumatic stress disorder.